MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
convertible notes
$10,250,000
Proceeds from
recapitalization
$265,827
Proceeds from notes
payable - related party
$50,000
Net cash flows
provided by financing...
$5,923,759
Canceled cashflow
$4,642,068
Net change in cash
$1,000,271
Canceled cashflow
$4,923,488
Repayment of convertible
notes
$3,032,645
Transaction costs paid in
connection with...
$907,499
Repayment of notes payable
related party
$701,924
Stock-based compensation
$14,131,250
Amortization of debt discount
$8,019,448
Accrued expenses
$1,047,088
Loss on
extinguishment of debt
-$364,109
Issuance of commitment
shares under eloc...
-$275,000
Prepaid expenses and
other current assets
-$174,254
Initial recognition of
forward purchase...
-$95,062
Net cash flows used
in operating...
-$4,923,488
Canceled cashflow
$24,106,211
Net loss
-$24,480,848
Change in fair value of
derivative liabilities and...
$3,860,889
Accounts payable
-$323,776
Inventories
$253,160
Other current
liabilities
-$111,026
Back
Back
Cash Flow
source: myfinsight.com
Aspire Biopharma Holdings, Inc. (ASBP)
Aspire Biopharma Holdings, Inc. (ASBP)